Stock comparison
Eli Lilly
Regencell Bioscience Holdings Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
RGC
Regencell Bioscience Holdings Limited
Market cap
$12.76B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | RGC | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 29F | LLY |
| Benjamin Graham | 86A | 16F | LLY |
| Philip Fisher |
Side-by-side metrics
| Metric | LLY | RGC |
|---|---|---|
| Market cap | $1T | $12.76B |
| P/E (TTM) | 36.6x | - |
| EV/EBIT | 34.1x | - |
| ROIC (TTM) | 32.06% | -4.44% |
| Gross margin | 83.51% | 0.0% |
| Net margin | 34.98% | 0.0% |
| Revenue CAGR 5y | 23.17% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- ROIC (TTM)32.06%vs -4.44%+107%
- Gross margin83.51%vs 0.0%+100%
- Net margin34.98%vs 0.0%+100%
- Dividend yield0.62%vs 0.0%
More like RGC
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.